Targeted therapy, particularly EGFR‐TKIs, has shown greater response rates and longer OS, compared with chemotherapy, in advanced NSCLC in the last decade,16, 17, 18 and it was recommended as the first‐line treatment for EGFR mutation‐positive advanced patients.13, 14, 15. This evidence concerns the gene EGFR and non-small cell lung carcinoma.